

DT-2179

DT-2179



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Wolfgang Barnikol
SERIAL NO. : 08/869,406
FILED : June 5, 1997
FOR : METHOD FOR THE PREPARATION OF
MOLECULARLY UNIFORM HYPERPOLYMERIC
HEMOGLOBINS

EXAMINER : Anish Gupta GROUP: 1654

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
APR 2 1998
GROUP 1800

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant respectfully requests that the documents listed on the attached form PTO-1449 be made of record and considered in connection with the examination of this application. Copies of the cited documents are enclosed. Translations of the foreign language documents are not readily available.

The references were cited in a European application corresponding to the present application.

International Application No. WO 92/21702 specifically discloses beta-beta cross-linked hemoglobins and method of preparation;

International Application No. WO 92/09630 discloses imidoester cross-linked compositions;

International Application No. WO 90/13309 discloses a hemoglobin composition and its use;

European Application No. 0 201 618 discloses a method of polymerization of hemoglobin with linked reagents characterized in that the hemoglobin is polymerized by reaction with polyfunctional agents, with the polyfunctional agents being fed from another phase so that an unhomogeneous polymerization takes place. The hemoglobin is polymerized in solutions with high concentration, with the production of polymers having a molecular weight from 60000 to more than 6×10^6 Dalton;

European Application No. 0 078 961 discloses a method of manufacturing of shelf-stable, interlaced hemoglobin compounds with a high oxygen-transporting capability and a hemoglobin compound produced by the method. According to the method, a

hemoglobin solution is treated with an oxygen-consuming reducing medium until $pO_2 = 0$ mbar and then with an effector. After the product is interlaced with dialdehyde it is reduced with a reducing medium specific for carbonyl groups, is ultrafiltrated, and then stabilized by admitting a reducing agent;

French Application No. 2,225,171 discloses a cross-linked, light-weight polyhemoglobin for use as a plasma substitute.

The Commissioner is hereby authorized to charge the fee required under 37 C.F.R. § 1.17(p) in the amount of \$240 and any additional fees, which may be required, to our Deposit Account No. 01-1944. A copy of this authorization is enclosed.

Respectfully submitted
for applicant,

Alexander Zinchuk

BY: *ALEXANDER ZINCHUK* / Reg. No. 30,541
for David Toren
Registration No. 19,468

Dated: March 17, 1998
ANDERSON KILL & OLICK, P.C.
1251 Avenue of the Americas
New York, New York 10021-1182
(212) 278-1000

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231 on March 17, 1998.

Alexander Zinchuk